MEIP MEI Pharma, Inc.

2.34
+0.04  (2%)
Previous Close 2.30
Open 2.27
Price To book 1.54
Market Cap 86.05M
Shares 36,772,000
Volume 843,163
Short Ratio 0.28
Av. Daily Volume 267,953

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b data due mid-2017.
ME-401
Chronic lymphocytic leukemia/small lymphocytic lymphoma or follicular lymphoma
Phase 2 commencement of dosing announced June 14, 2017 - data from first stage due 1Q 2018.
Pracinostat in combination with Vidaza
High-risk Myelodysplastic Syndrome (MDS)
Phase 2 topline data released late March 2015 did not meet primary endpoint
Pracinostat in combination with Vidaza
First line intermediate-2 or high-risk Myelodysplastic Syndrome
Ongoing
Pracinostat and Vidaza or Dacogen
Myelodysplastic Syndrome
Phase 3 trial to commence June 2017. Phase 2 presentation at ASCO June 5, 2017.
Pracinostat in combination with Vidaza
Elderly patients with newly diagnosed acute myeloid leukemia (AML)

Latest News

  1. Shire (SHPG) Receives MAA Validation for Veyvondi by EMA
  2. Indivor's Opioid Use Disorder Drug Meets Primary Endpoint
  3. Horizon Pharma Gets Health Canada Approval for Procysbi
  4. Seattle Genetics Halts Phase III Study on Leukemia Drug
  5. Mallinckrodt Initiates Amyotrophic Lateral Sclerosis Study
  6. Omeros (OMER) Hits New 52-Week High on Positive FDA Decision
  7. Omeros (OMER) Lead Candidate Gets Breakthrough Designation
  8. Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug
  9. Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome
  10. Seres Therapeutics' Stock Up as SER-109 Moves to Phase III
  11. Intercept (ICPT) Releases Data from Phase II Flint Trial
  12. Alkermes Commences Phase III Study for Schizophrenia Drug
  13. Mallinckrodt (MNK) Commences Phase III Study of StrataGraft
  14. Seattle Genetics Reports Updated Results on Cancer Drug
  15. Radius (RDUS) Announces Positive Data on Breast Cancer Drug
  16. Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
  17. Novo Nordisk's (NVO) Drug Gets FDA Approval for Hemophilia B
  18. Today's Research Reports on Stocks to Watch: Catalyst Biosciences and MEI Pharma
  19. Ligand (LGND) Signs Licensing Deal with xCella Biosciences